New drug targets 'Undruggable' cancer mutations in early human trial
Disease control
Recruiting now
This early-stage trial is testing a new drug called WEF-001 in people with advanced cancers that have a specific KRAS mutation. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, colorectal, and lung cancer that have stopped respo…
Phase: PHASE1, PHASE2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC